Matinas BioPharma Holdings (MTNB) Receivables (2018 - 2023)

Matinas BioPharma Holdings (MTNB) has 5 years of Receivables data on file, last reported at $8.2 million in Q4 2023.

• Receivables for Q4 2023 came in at $8.2 million, up 125.31% year-over-year; the trailing twelve-month figure through Dec 2023 was $8.2 million (up 125.31% YoY), and the FY2023 annual result was $8.2 million, up 125.31% from the prior year.
• Receivables grew to $8.2 million in Q4 2023 per MTNB's latest filing, from $3.6 million in the prior quarter.
• Over five years, Receivables peaked at $8.2 million in Q4 2023 and troughed at $650000.0 in Q4 2020.
• A 4-year average of $3.5 million and a median of $3.6 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables jumped 267.35% in 2022, then changed 0.0% in 2023.
• A 4-year view of Receivables shows it stood at $650000.0 in 2020, then jumped by 50.77% to $980000.0 in 2021, then soared by 270.92% to $3.6 million in 2022, then soared by 125.31% to $8.2 million in 2023.
• Business Quant data shows MTNB's Receivables at $8.2 million in Q4 2023, $3.6 million in Q3 2023, and $3.6 million in Q2 2023.